Genialis a Winner in Inc.’s 2023 Best in Business Awards in AI & Data
To build a great company, and a great business, [...]
RNA Biomarkers in Focus: Key Takeaways from SITC and ESMO
Genialis recently took part in two pivotal conferences in [...]
Genialis Presents Data at SITC 2023 on RNA-Based Biomarkers to Predict Immunotherapy Response
The Xerna TME panel identified nearly 50 percent of [...]
Prevalence of genomic alterations in Xerna tumor microenvironment subtypes in colorectal cancer patients
This study explores the distribution of genomic alterations in [...]
Profiling microsatellite instability using RNA sequencing data
This study introduces a machine learning model that uses [...]
New Medicines from Evolutionary Pathways: Using Comparative Genomics to Treat Human Disease | TPM podcast #33
Welcome to Talking Precision Medicine (TPM podcast) — the [...]
Genialis and Cancer Research Horizons Collaborate to Develop AI-Driven Patient Classifiers
Partnership provides high-quality and clinically relevant data for modeling [...]
Genialis Presents ResponderID KRAS, a Biomarker Framework for Predicting Patient Response
Genialis points ResponderID, its innovative biomarker framework combining machine [...]
ResponderID™ KRAS: Biology-Driven Machine Learning to Personalize KRAS Inhibitor Therapeutics
Traditional biomarkers often fail to capture the dynamic nature [...]
Clinical Drug Discovery Veterans Join Genialis’ Efforts to Build Better Biomarkers for Precision Oncology
Class of new hires bring diverse expertise across numerous functions [...]
